Adalimumab is a self-injectable biologic therapy that has received approval from the China Food and Drug Administration (CFDA, now NMPA) for four indications: rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and polyarticular juvenile idiopathic arthritis.

AccuSift provides high-performance competitive antibody pairs for adalimumab detection. These reagents offer exceptional inter-batch consistency and are optimized specifically for IVD kit development, including lateral flow assays, chemiluminescence, ELISA, and POCT platforms. Featuring high affinity and high specificity, they enable rapid and reliable detection.

Sensitivity: ELISA LOD: 50 ng/mL